Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories
1
TL;DR: The INTERHEART study as discussed by the authors reported that dyslipidaemia is the main risk factor for CVD in 15,152 cases and 14,820 controls, from 52 countries.
read more
Abstract: The INTERHEART study (15,152 cases and 14,820 controls, from 52 countries) [1] reported that among modifiable cardiovascular disease (CVD) predictors, dyslipidaemia is the main risk factor [1]. Dys...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Guidelines for dyslipidemia management in India: A review of the current scenario and gaps in research
TL;DR: A systematic search was performed in PubMed, Google Scholar, Cochrane Library and Science Direct to obtain relevant articles as discussed by the authors , highlighting the need for formulating Indian dyslipidemia management guidelines and CV risk estimation algorithms.
11
References
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Vasilios G. Athyros,Konstantinos Tziomalos,Thomas D. Gossios,Theodora Griva,Panagiotis Anagnostis,Konstantinos Kargiotis,Efstathios D. Pagourelias,Eleni Theocharidou,Asterios Karagiannis,Dimitri P. Mikhailidis +9 more
TL;DR: Statin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild-to-moderately abnormal liver tests that are potentially attributable to non-alcoholic fatty liver disease.
686
Statin use and non-alcoholic steatohepatitis in at risk individuals
Paola Dongiovanni,Salvatore Petta,Ville Männistö,Rosellina Margherita Mancina,Rosaria Maria Pipitone,Vesa Kärjä,Marco Maggioni,Pirjo Käkelä,Olov Wiklund,Enrico Mozzi,Stefania Grimaudo,Dorota Kaminska,Raffaela Rametta,Antonio Craxì,Silvia Fargion,Valerio Nobili,Stefano Romeo,Stefano Romeo,Jussi Pihlajamäki,Luca Valenti +19 more
TL;DR: Statin use was associated with protection towards the full spectrum of liver damage in individuals at risk of non-alcoholic steatohepatitis, however, the I148M PNPLA3 risk variant limited this beneficial effect.
373
Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey
Stein Hallan,Ketil Dahl,Cecilia Montgomery Oien,Diana C. Grootendorst,Arne Aasberg,Jostein Holmen,Friedo W. Dekker +6 more
TL;DR: Screening people with hypertension, diabetes mellitus, or age >55 was the most effective strategy to detect patients with chronic kidney disease, but the risk of end stage renal disease among those detected was low.
369
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
TL;DR: There is a significant under usage of medications for secondary prophylaxis and this is more striking in low-income countries, with greatest variation in poorest countries.
167
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Konstantinos Kargiotis,Vasilios G. Athyros,Olga Giouleme,Niki Katsiki,Evangelia Katsiki,Panagiotis Anagnostis,Chrysoula Boutari,Michael Doumas,Asterios Karagiannis,Dimitri P. Mikhailidis +9 more
TL;DR: It is suggested that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve MetS within 12 mo and the reduction of fasting plasma glucose and SUA levels may reduce the risk of vascular and liver morbidity and mortality in NASH patients.
139